The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo Qvantig for subcutaneous use to treat various solid tumours. This new combination product ...
The approval of Opdivo Qvantig, a subcutaneous version of Opdivo, offers faster administration, potential market share gains, and extended patent protection into the 2030s. BMY's strategic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback